Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

third quarter of 2011, Alimta generated sales of $629.7 million, an increase of 12 percent compared with the third quarter of 2010. U.S. sales of Alimta increased 5 percent, to $258.9 million, driven by increased demand. Sales outside the U.S. increased 18 percent, to $370.8 million, due to the favorable impact of foreign exchange rates, as well as increased demand.

Humalog

For the third quarter of 2011, worldwide Humalog sales increased 20 percent, to $593.2 million. Sales in the U.S. increased 20 percent to $345.5 million, driven by increased demand and, to a lesser extent higher prices. Sales outside the U.S. increased 21 percent to $247.7 million, due to the favorable impact of foreign exchange rates, as well as increased demand.

Cialis

Cialis sales for the third quarter of 2011 increased 16 percent to $469.8 million. U.S. sales of Cialis were $168.2 million in the third quarter, a 10 percent increase compared with the third quarter of 2010, driven primarily by higher prices. Sales of Cialis outside the U.S. increased 19 percent, to $301.6 million, driven by the favorable impact of foreign exchange rates and, to a lesser extent higher prices and increased demand.

Humulin

Worldwide Humulin sales increased 8 percent in the third quarter of 2011, to $301.5 million. U.S. sales increased 18 percent to $142.6 million, driven primarily by higher prices for Humulin, as well as increased demand for Humulin® ReliOn®. Sales outside the U.S. increased 1 percent, to $158.9 million, driven by the favorable impact of foreign exchange rates, offset by lower prices.

Evista

Evista sales were $270.1 million in the third quarter of 2011, a 5 percent increase compared with the third quarter of 2010. U.S. sales of Evista increased 6 percent to $176.8 million, driven by higher prices, partially offset by lower volume. Sales outside the U.S. increased 3 percent to $93.3 million, driven by the favorable impact of foreign
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 The Parenteral Drug Association is ... Board of Professional Engineers and Land Surveyors ... to professional engineers for continuing professional competency (CPC) credits. ... value and quality of PDA,s professional education offerings," said ... and hands-on professional training at the Training and Research ...
(Date:6/29/2015)... , June 29, 2015  VisionCare Ophthalmic ... visual prosthetic devices for the treatment of ... publication of "Long-Term (60-month) Results for the ... Stratified by Age in Patients with End-Stage ... . The 5-year data show substantial retention ...
(Date:6/29/2015)... June 29, 2015 Dermatological drugs ... revenues ,Where is the market for dermatological drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 310 page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8
... at the 2011 Pharmaceutical Care Management Association (PCMA),s ... President and CEO Eric Elliott speak about the ... managers as health care reform is implemented, industry ... the market and the pipeline of new treatments ...
... DALLAS, Feb. 8, 2011 ... known for its expertise in understanding consumer data, translating ... effective creative with measurable results, today announced that Peter ... Strategy - Healthcare.  Dannenfelser, a pharmaceutical marketing executive with ...
Cached Medicine Technology:Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 3
(Date:6/30/2015)... ... June 30, 2015 , ... This Fourth of July, Peacock ... Alley story including hard work, tenacity, perseverance, commitment to quality, honesty and love of ... Born of Mary Ella Gabler's simple love of quilts, Peacock Alley was fully realized ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
(Date:6/29/2015)... ... 29, 2015 , ... The Society for Immunotherapy of Cancer ... granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic ... of nivolumab for patients with metastatic melanoma in Europe represents a major advance ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
... a voluntary,recall of two types of its Meijer Brand dry-roasted ... in all of its stores in Michigan, Ohio,Indiana, Illinois and ... stations. All sell-by dates are impacted by this recall. , ... items:, -- Meijer Bulk Dry Roasted Peanuts, ...
... 2 alcohol-metabolizing enzymes are responsible, study says , , ... the DNA of certain genes can increase the ... according to researchers who reviewed studies on alcohol ... analysis suggests that such variations, called gene polymorphisms, ...
... Clinicians in an increasing number of countries can now ... the clinical management of osteoporosis. , FRAX, which ... February 2008. It was developed by Professor John A. ... Metabolic Bone Diseases at the University of Sheffield Medical ...
... Partners, a national,investment banking firm headquartered in Nashville, ... as a senior research analyst covering the,healthcare services ... to Avondale Partners from Credit Suisse in New ... behavioral health care providers.,Prior to that he covered ...
... Physicians Healthcare Management Group, Inc. (Phyhealth) ... maintenance organizations (HMOs) in partnership with physicians and ... malpractice insurer, today released the following letter to ... year, a new Congress and a new administration ...
... these treatments for menopausal symptoms, FDA says , , ... as "bio-identical" hormones or "bio-identical hormone replacement therapy," ... menopausal women lose weight to preventing senility. , ... effective than conventional hormone-replacement therapy. , But the ...
Cached Medicine News:Health News:Meijer Announces Voluntary Recall for Some Meijer Brand Peanuts and Ice Cream Novelties Citing Possible Health Risk 2Health News:Variations in Gene DNA Boost Drinkers' Cancer Risk 2Health News:FRAX tool now available for use in 12 countries 2Health News:Avondale Partners Expands Coverage With Healthcare Analyst 2Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4Health News:The Truth About 'Bio-identical' Hormone Therapy 2Health News:The Truth About 'Bio-identical' Hormone Therapy 3Health News:The Truth About 'Bio-identical' Hormone Therapy 4
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: